Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension

Heng-Xuan Cai; Chen-Chen Liang; Shan-Jie Wang; Jun-Chen Guo; Ye Wang; Bo Yu; Xue-Qin Gao; Shao-Hong Fang

doi:10.11909/j.issn.1671-5411.2022.07.003

Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension

J Geriatr Cardiol. 2022 Jul 28;19(7):511-521. doi: 10.11909/j.issn.1671-5411.2022.07.003.

Authors

Heng-Xuan Cai^{1

2}, Chen-Chen Liang^{1

2}, Shan-Jie Wang^{1

2}, Jun-Chen Guo^{1

2}, Ye Wang^{1

2}, Bo Yu^{1

2}, Xue-Qin Gao^{1

2}, Shao-Hong Fang^{1

2}

Affiliations

¹ Department of Cardiology, the Second Afﬁliated Hospital of Harbin Medical University, Harbin, China.
² The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China.

PMID: 35975019
PMCID: PMC9361161
DOI: 10.11909/j.issn.1671-5411.2022.07.003

Abstract

Background: It is controversial whether angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) have a potentially beneficial role in the respiratory system. This study investigated the association between ACEI/ARB medications and respiratory-related mortality in hypertensive patients in a real-world nationally representative cohort.

Methods: This was a retrospective analysis based on a prospective cohort study. A total of 10,530 patients with hypertension aged ≥ 20 years were included. The data was extracted from the US National Health and Nutrition Examination Survey during 1988-1994 and 1999-2006. The study was approved by the Institutional Review Boards. Moreover, inform concent was taken form all the participants.

Results: Overall, 27.7% (n = 2920) patients took ACEI/ARB agents. During a median follow-up of 12.4 years, 278 individuals died of respiratory disease, including chronic lower respiratory disease (n = 155) and inﬂuenza or pneumonia (n = 123). Compared with the patients without ACEI/ARB use, those taking ACEI/ARB were not associated with respiratory-specific mortality in a multivariable-adjusted Cox model. After 1: 1 matching, taking ACEI/ARB was also not related to respiratory mortality (Hazard ratio (HR) = 1.07, 95% CI: 0.79-1.43), inﬂuenza- or pneumonia-related (HR = 1.00, 95% CI: 0.65-1.54) and chronic pulmonary mortality (HR = 1.13, 95% CI: 0.75-1.69). After separating ACEI and ARB from anti-hypertensive medications, those associations remained unchanged.

Conclusions: We discovered no significant link between ACEI or ARB medication and pulmonary-related mortality in hypertensive patients. In hypertensive patients, standard ACEI/ARB administration may have little effect on the respiratory system.